Q-omics provides the consensus-scored PTCHD1 profile across patient tissues and cancer cell-line models. PTCHD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTCHD1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PTCHD1 RNA expression shows 12,245 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight ACC, COAD, and SARC as cancer lineages where PTCHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCHD1 survival associations across molecular data types. PTCHD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCHD1 RNA expression–survival associations across cancer types. High PTCHD1 expression shows unfavorable associations in ACC, MESO, LGG, LUAD and UVM, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTCHD1 RNA expression.
This table summarizes PTCHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PTCHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCHD1 shows lower tumor expression in COAD, KICH, LUSC, BLCA, LUAD and KIRC. The COAD box plot shows higher PTCHD1 RNA expression in normal versus tumor tissue (log2 FC = −0.820, t-test p < 0.001).
This table shows molecular features associated with PTCHD1 in patient tissues and cancer cell lines. In patient samples, PTCHD1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTCHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
